+

WO2009070564A3 - Compositions and methods for prevention of infection in transcutaneous osseointegrated implants - Google Patents

Compositions and methods for prevention of infection in transcutaneous osseointegrated implants Download PDF

Info

Publication number
WO2009070564A3
WO2009070564A3 PCT/US2008/084640 US2008084640W WO2009070564A3 WO 2009070564 A3 WO2009070564 A3 WO 2009070564A3 US 2008084640 W US2008084640 W US 2008084640W WO 2009070564 A3 WO2009070564 A3 WO 2009070564A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
preventing
transcutaneous
relates
wound
Prior art date
Application number
PCT/US2008/084640
Other languages
French (fr)
Other versions
WO2009070564A2 (en
Inventor
Roy D. Bloebaum
Cathy Petti
Juliana Szakacs
Teri G.R. Chou
Original Assignee
Macrochem Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrochem Corporation filed Critical Macrochem Corporation
Publication of WO2009070564A2 publication Critical patent/WO2009070564A2/en
Publication of WO2009070564A3 publication Critical patent/WO2009070564A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to a method of preventing wound infection by administering a therapeutic formulation comprising a peptide to a wound site. More specifically, the invention relates to the use of amphiphilic peptides in preventing and treating infections. The invention also relates to preventing wound infectionin a host by administering a biologically active amphiphilic peptide or biologically active protein to a host having a wound wherein the peptide or protein is administered in an amount effective to prevent wound infection. Even more specifically the invention relates to the use of cationic amphiphilic peptides in preventing and treating infections associated with transcutaneous osseointegreated implants.
PCT/US2008/084640 2007-11-27 2008-11-25 Compositions and methods for prevention of infection in transcutaneous osseointegrated implants WO2009070564A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99043007P 2007-11-27 2007-11-27
US60/990,430 2007-11-27

Publications (2)

Publication Number Publication Date
WO2009070564A2 WO2009070564A2 (en) 2009-06-04
WO2009070564A3 true WO2009070564A3 (en) 2009-08-27

Family

ID=40679204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/084640 WO2009070564A2 (en) 2007-11-27 2008-11-25 Compositions and methods for prevention of infection in transcutaneous osseointegrated implants

Country Status (1)

Country Link
WO (1) WO2009070564A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602762B (en) * 2012-06-12 2017-04-05 帝普休姆制药有限公司 Stable pexiganan formula

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012174373A1 (en) * 2011-06-16 2012-12-20 Dipexium Pharmaceuticals Methods of treating and inhibiting pathogens with resistance-mechanisms
NL2021630B1 (en) * 2018-09-14 2020-05-06 Stichting Katholieke Univ Polyurethane sheet
WO2020043834A1 (en) * 2018-08-30 2020-03-05 Stichting Katholieke Universiteit Polyurethane sheet

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045531A (en) * 1989-12-18 1991-09-03 Magainin Sciences Inc. Wound treatment employing biologically active ion channel forming peptides and proteins
US5792831A (en) * 1990-02-08 1998-08-11 Magainin Pharmaceuticals Inc. Analogues of magainin peptides containing D-amino acids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045531A (en) * 1989-12-18 1991-09-03 Magainin Sciences Inc. Wound treatment employing biologically active ion channel forming peptides and proteins
US5792831A (en) * 1990-02-08 1998-08-11 Magainin Pharmaceuticals Inc. Analogues of magainin peptides containing D-amino acids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOPINATH, D. ET AL.: "Pexiganan-incorporated collagen matrices for infected wound-healing processes in rat.", J. BIOMED. MATER. RES. PTA, vol. 73, no. 3, 2005, pages 2666 - 2672 *
ROTEM, S. ET AL.: "Physicochemical properties that enhance discriminative antibacterial activity of short dermaseptin derivatives", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 50, no. 8, 2006, pages 1161 - 1168 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602762B (en) * 2012-06-12 2017-04-05 帝普休姆制药有限公司 Stable pexiganan formula

Also Published As

Publication number Publication date
WO2009070564A2 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
WO2009129437A3 (en) Methods and compositions for treating post-operative pain comprising clonidine
BRPI0514420A (en) peptide, variant thereof, or a pharmaceutically acceptable salt thereof, composition, use of a peptide or peptide variant, substrate, and methods of treating or preventing a microbial infection, and treating a wound in an individual
WO2009129509A3 (en) Methods and compositions for treating post-operative pain comprising a local anesthetic
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
EP1933833B8 (en) Therapy for the treatment of overactive bladder
WO2008021113A3 (en) Transdermal methods and systems for treating alzheimer's disease
TW200612987A (en) Combination treatment for non-hematologic malignancies
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
WO2007100675A3 (en) Collagenase for treating cellulite
WO2007108990A3 (en) Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
WO2007102686A8 (en) Peptides having activities of insulin like growth factor-1 and their uses
WO2006135493A3 (en) A composition for wound healing and use thereof
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2006073786A3 (en) Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
WO2010045417A3 (en) Combination therapies for the treatment of obesity
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
MX2012004409A (en) Recombinant human cc10 protein for treatment of influenza.
WO2007014253A3 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
WO2009070564A3 (en) Compositions and methods for prevention of infection in transcutaneous osseointegrated implants
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08855099

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22.10.2010)

122 Ep: pct application non-entry in european phase

Ref document number: 08855099

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载